Quarterly report pursuant to Section 13 or 15(d)

Licenses Acquired (Tables)

v3.8.0.1
Licenses Acquired (Tables)
 3 Months Ended
Mar. 31, 2018
Research and Development Arrangement, Contract to Perform for Others
As such, for the three months ended March 31, 2018 and 2017, the purchase price of licenses acquired was classified as research and development-licenses acquired in the Condensed Consolidated Statements of Operations, as reflected in the table below:
 
 
 
For the Three Months Ended March 31,
 
($ in thousands)
 
2018
 
2017
 
Fortress Companies:
 
 
 
 
 
 
 
Checkpoint
 
$
–
 
$
400
 
Helocyte
 
 
21
 
 
–
 
Mustang
 
 
75
 
 
575
 
Cellvation
 
 
1
 
 
–
 
Caelum
 
 
–
 
 
219
 
Cyprium
 
 
–
 
 
100
 
Total
 
$
97
 
$
1,294
 
Checkpoint Therapeutics, Inc [Member]  
Schedule of Licenses Acquired Expenses [Table Text Block]
The table below provides a summary of Checkpoint’s expense related to its licenses, for the three months ended March 31, 2018 and 2017 by license as recorded in the Condensed Consolidated Statements of Operations:
 
($ in thousands)
 
For the three months ended March 31
 
 
 
2018
 
2017
 
Jubliant Biosys License CK-103
 
$
–
 
$
400
 
Total licenses acquired expense
 
$
–
 
$
400
 
Mustang Therapeutics, Inc [Member]  
Schedule of Licenses Acquired Expenses [Table Text Block]
The table below provides a summary of Mustang’s expense related to its licenses, for the three months ended March 31, 2018 and 2017 by license as recorded in the Condensed Consolidated Statements of Operations:
 
($ in thousands)
 
For the three months ended March 31
 
 
 
2018
 
2017
 
City of Hope (COH) IL-13 License
 
$
–
 
$
250
 
COH IV/ICV Agreement
 
 
–
 
 
125
 
University of California License for PSCA
 
 
–
 
 
200
 
Manufacturing License
 
 
75
 
 
–
 
Total licenses acquired expense
 
$
75
 
$
575